现成预导管内分支支架移植物治疗肾旁主动脉瘤的真实世界评价
在2个中心回顾性分析2021年1月至2023年6月连续21例肾旁腹主动脉瘤患者,接受E-nside预导管内分支支架移植物,平均随访14±7.7个月。技术成功率为95%,12个月无靶血管不稳定及再干预率为95%,随访期间无I型或III型内漏。
要点
- 技术成功率为95%,1例需髂股导管推进装置。
- 112枚桥接支架中1枚(1%,右肾动脉)于30天闭塞,12个月无靶血管不稳定及再干预率为95%。
- 1例(5%)于13个月死于非动脉瘤相关原因,1例(5%)发生脊髓缺血。
核心结论
- E-nside支架移植物在本研究中显示出令人鼓舞的结果;但作者强调主动脉覆盖范围要求生产截短型变体。
研究设计与样本
- 2021年1月至2023年6月,在2个中心对连续肾旁腹主动脉瘤患者接受E-nside预导管内分支支架移植物进行回顾性分析,数据为前瞻性收集;共21例(20例男性,平均年龄71岁),平均随访14±7.7个月。
主要发现
- 技术成功率为95%,1例需使用髂股导管推进装置;112枚桥接支架中1枚(1%,右肾动脉)于30天闭塞。
- 12个月无靶血管不稳定及再干预率为95%;随访期间未发现I型或III型内漏。
- 1例(5%)于13个月死于非动脉瘤相关原因,1例(5%)发生脊髓缺血;未观察到其他主要围手术期并发症。
- 平均腹腔干以上主动脉覆盖达52±8%。
- 9例(43%)为症状性动脉瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze the early performance and efficacy of the first commercially available off-the-shelf precannulated multibranched endograft in the endovascular repair of pararenal abdominal aortic aneurysms (PAAAs). The device received European marketing approval in late 2020. MATERIALS AND METHODS: Between January 2021 and June 2023, a retrospective analysis of prospectively collected data from all consecutive patients with pAAAs undergoing implantation of the E-nside precannulated inner-branched endograft was conducted in 2 centers. The primary outcome measure was technical success defined as the composite endpoint of successful (1) delivery of the 24F endograft, (2) use of the precannulation tubes, and (3) implantation of the bridging stent-grafts (BSGs) to the target vessels. Main secondary endpoints were mortality, target vessel instability (TVI), absence of type I or III endoleak, reintervention, spinal cord ischemia, and supra-celiac aortic coverage. RESULTS: Twenty-one patients (20 men, mean age: 71 years) were included in this study with a mean follow-up of 14±7.7 months. Nine patients had a symptomatic aneurysm (43%). Technical success amounted to 95% (in one patient, an iliofemoral conduit was necessary to advance the device). One out of 112 BSGs (1%, right renal artery) occluded at 30 days, resulting in freedom from TVI and reintervention rate at 12 months of 95%. No type I or III endoleaks were identified during follow-up. One patient (5%) died at 13 months due to non-aneurysm-related death, and 1 patient (5%) developed spinal cord ischemia. No other major perioperative complications were observed. Mean supra-celiac aortic coverage reached 52±8%. CONCLUSIONS: Given the imperative need for an off-the-shelf endograft tailored to address PAAAs, the E-nside stent-graft demonstrated encouraging outcomes in this study. Nevertheless, it is essential to emphasize that the extent of aortic coverage mandates the production of a truncated variant.Clinical ImpactThe endovascular repair of urgent pararenal aortic aneurysms remains still an unsolved problem in the endovascular era since there are no available off-the-shelf dedicated fenestrated or branched endografts. This paper confirms the safety and efficacy of the off-the-shelf precannulated inner branched endograft for this specific indication.
引用
- Bisdas T, Zambas N, Zertalis M, et al. Real-World Evaluation of the Off-the-Shelf Precannulated Inner-Branched Endograft for Pararenal Aortic Aneurysms. J Endovasc Ther. 2024. PMID: 38528651. doi:10.1177/15266028241241006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。